Citations

Clear

16281 citation(s) found for "Yu, David".

Kidney after liver transplantation does not have an increased risk of rejection compared to liver alone
Ghali, Peter , Ibrahim, Ramez , Hodge, David O. , White, Launia J. , Wadei, Hani M. , Ibrahim, Ramez M , Hodge, David, White, Launia, Wadei, Hani M

Mayo Clinic

Clinical Transplantation | April 15, 2024 | Volume: 38 | Issue: 4 | Pages: No page available

10.1111/ctr.15311 | PMID 38616569 Get It

AbstractBackgroundSimultaneous liver kidney (SLK) transplant protects against acute cellular rejection. In 2017, UNOS implemented a “safety net” policy to allow patients with renal recovery to avoid renal transplantation. Whether kidney after liver transplantation (KALT) increases the risk of rejection is unknown.MethodsWe performed a retrospective analysis of the Organ Procurement and Transplantation Network (OPTN) database of adult patients who received liver transplant, SLK or KALT between 2010 and 2020. We examined rejection of the liver within 6 months and 1 year of the liver transplant, as well as rejection of the kidney within 6 months and 1 year of receiving the kidney, as well as patient and graft loss.ResultsSixty‐six thousand seventy‐nine patients were transplanted; 60 168 with liver transplant alone, 5627 with SLK, and 284 with KALT. Acute or chronic liver rejection rates within 6 or 12 months were statistically higher in the KALT group (10.0% and 10.9%) compared to the SLK group (6.1% and 7.5%), but comparable to the LTA group (9.3% and 11.1%). Kidney rejection and graft survival rates were not different. Liver graft survival was worse in KALT than SLK or LTA (Kaplan‐Meier estimates .61 vs. .89 and .90), but these patients were more ill at the time of transplantation. KDPI and LDRI scores were notably lower in the SLK than KALT group. Patient survival was not clinically different between the groups.ConclusionKALT does not increase the risk of acute or chronic kidney rejection. SLK has a lower risk of early liver rejection, but this effect diminishes by one year to being not clinically different compared to KALT. Given that KALT is immunologically safe, and potentially avoids unnecessary renal graft use, it should be preferred over SLK.Brief summaryPatients undergoing sequential kidney after liver transplant do not have an increased risk of liver or kidney rejection when compared to liver transplant alone or simultaneous liver and kidney transplant.
Hypertrophic cardiomyopathy detection with artificial intelligence electrocardiography in international cohorts: an external validation study
Siontis, Konstantinos C. , Wieczorek, Mikolaj A. , Maanja, Maren , Hodge, David O. , Kim, Hyung‐Kwan , Lee, Heesun , Lim, Jaehyun , Ariga, Rina, Mahmod, Masliza , Ackerman, Michael J. , Friedman, Paul A. , Raman, Betty , Mahmod, Masliza , Watkins, Hugh , Neubauer, Stefan , Windecker, Stephan , Ackerman, Michael J , Friedman, Paul A , Kim, Hyung-Kwan , Lee, Hyun‐Jung , Park, Chan Soon , Watkins, Hugh , Windecker, Stephan , Siontis, George C.M. , Gersh, Bernard J. , Attia, Zachi I. , Noseworthy, Peter A.

Mayo Clinic

European Heart Journal - Digital Health | April 13, 2024 | Volume: 5 | Issue: 4 | Pages: 416-426

10.1093/ehjdh/ztae029 | PMID 39081936 Get It

Abstract Aims Recently, deep learning artificial intelligence (AI) models have been trained to detect cardiovascular conditions, including hypertrophic cardiomyopathy (HCM), from the 12-lead electrocardiogram (ECG). In this external validation study, we sought to assess the performance of an AI-ECG algorithm for detecting HCM in diverse international cohorts. Methods and results A convolutional neural network-based AI-ECG algorithm was developed previously in a single-centre North American HCM cohort (Mayo Clinic). This algorithm was applied to the raw 12-lead ECG data of patients with HCM and non-HCM controls from three external cohorts (Bern, Switzerland; Oxford, UK; and Seoul, South Korea). The algorithm’s ability to distinguish HCM vs. non-HCM status from the ECG alone was examined. A total of 773 patients with HCM and 3867 non-HCM controls were included across three sites in the merged external validation cohort. The HCM study sample comprised 54.6% East Asian, 43.2% White, and 2.2% Black patients. Median AI-ECG probabilities of HCM were 85% for patients with HCM and 0.3% for controls (P < 0.001). Overall, the AI-ECG algorithm had an area under the receiver operating characteristic curve (AUC) of 0.922 [95% confidence interval (CI) 0.910–0.934], with diagnostic accuracy 86.9%, sensitivity 82.8%, and specificity 87.7% for HCM detection. In age- and sex-matched analysis (case–control ratio 1:2), the AUC was 0.921 (95% CI 0.909–0.934) with accuracy 88.5%, sensitivity 82.8%, and specificity 90.4%. Conclusion The AI-ECG algorithm determined HCM status from the 12-lead ECG with high accuracy in diverse international cohorts, providing evidence for external validity. The value of this algorithm in improving HCM detection in clinical practice and screening settings requires prospective evaluation.
Machine learning for enhanced prognostication: predicting 30-day outcomes following posterior fossa decompression surgery for Chiari malformation type I in a pediatric cohort
Elmi‐Terander, Adrian , Ahn, Edward S. , Bydon, Mohamad , Elmi-Terander, Adrian , El-Hajj, Victor Gabriel , El-Hajj, Victor Gabriel , Ghaith, Abdul Karim , Daniels, David J.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | April 13, 2024 | Volume: 34 | Issue: 1 | Pages: 57-65

10.3171/2024.2.peds23523 | PMID 38608292 Get It

OBJECTIVE Chiari malformation type I (CM-I) is a congenital disorder occurring in 0.1% of the population. In symptomatic cases, surgery with posterior fossa decompression (PFD) is the treatment of choice. Surgery is, however, associated with peri- and postoperative complications that may require readmission or renewed surgical intervention. Given the associated financial costs and the impact on patients’ well-being, there is a need for predictive tools that can assess the likelihood of such adverse events. The aim of this study was therefore to leverage machine learning algorithms to develop a predictive model for 30-day readmissions and reoperations after PFD in pediatric patients with CM-I. METHODS This was a retrospective study based on data from the National Surgical Quality Improvement Program–Pediatric database. Eligible patients were those undergoing PFD (Current Procedural Terminology code 61343) for CM-I between 2012 and 2021. Patients undergoing surgery for tumors or vascular lesions were excluded. Unplanned 30-day readmission and unplanned 30-day reoperation were the main study outcomes. Additional outcome data considered included the length of hospital stay, 30-day complications, discharge disposition, and 30-day mortality. Training and testing samples were randomly generated (80:20) to study the 30-day readmission and reoperation using logistic regression, decision tree, random forest (RF), K-nearest neighbors, and Gaussian naive Bayes algorithms. RESULTS A total of 7106 pediatric patients undergoing PFD were included. The median age was 9.2 years (IQR 4.7, 14.2 years). Most of the patients were female (56%). The 30-day readmission and reoperation rates were 7.5% and 3.4%, respectively. Headaches (32%) and wound-related complications (30%) were the most common reasons for 30-day readmission, while wound revisions and evacuation of fluid or blood (62%), followed by CSF diversion-related procedures (28%), were the most common reasons for 30-day reoperation. RF classifiers had the highest predictive accuracy for both 30-day readmissions (area under the curve [AUC] 0.960) and reoperations (AUC 0.990) compared with the other models. On feature importance analysis, sex, developmental delay, ethnicity, respiratory disease, premature birth, hydrocephalus, and congenital/genetic anomaly were some of the variables contributing the most to both RF models. CONCLUSIONS Using a large-scale nationwide dataset, machine learning models for the prediction of both 30-day readmissions and reoperations were developed and achieved high accuracy. This highlights the utility of machine learning in risk stratification and surgical decision-making for pediatric CM-I.
Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy
Friedman, Joshua, Yabe, Mariko , Petrova‐Drus, Kseniya , Pulitzer, Melissa , Busam, Klaus J. , Rampal, Raajit K. , Ulaner, Gary A. , Reddy, Ryan , Yeh, Randy , Rotemberg, Veronica , Hershkovitz‐Rokah, Oshrat , Shpilberg, Ofer , Abeykoon, Jithma P. , Fidai, Shiraz , Gannamani, Vedavyas, Zia, Maryam, Panageas, Katherine S. , Rosenblum, Marc K. , Durham, Benjamin H. , Reiner, Anne S , Mazor, Roei D , Hershkovitz-Rokah, Oshrat , Goyal, Guarav , Abeykoon, Jithma P , Diamond, Eli L , Ulaner, Gary , Reiner, Anne S. , Doǧan, Ahmet , Francis, Jasmine H. , Hatzoglou, Vaios , Lacouture, Mario E. , Mazor, Roei David , Goyal, Gaurav , Go, Ronald S. , Rech, Karen L. , Morlote, Diana M. , Abdel‐Wahab, Omar , Diamond, Eli L.

Mayo Clinic

British Journal of Haematology | April 13, 2024 | Volume: 205 | Issue: 1 | Pages: 127-137

10.1111/bjh.19462 | PMID 38613141 Get It

Summary Histiocytic neoplasms are diverse clonal haematopoietic disorders, and clinical disease is mediated by tumorous infiltration as well as uncontrolled systemic inflammation. Individual subtypes include Langerhans cell histiocytosis (LCH), Rosai–Dorfman–Destombes disease (RDD) and Erdheim–Chester disease (ECD), and these have been characterized with respect to clinical phenotypes, driver mutations and treatment paradigms. Less is known about patients with mixed histiocytic neoplasms (MXH), that is two or more coexisting disorders. This international collaboration examined patients with biopsy‐proven MXH with respect to component disease subtypes, oncogenic driver mutations and responses to conventional (chemotherapeutic or immunosuppressive) versus targeted (BRAF or MEK inhibitor) therapies. Twenty‐seven patients were studied with ECD/LCH (19/27), ECD/RDD (6/27), RDD/LCH (1/27) and ECD/RDD/LCH (1/27). Mutations previously undescribed in MXH were identified, including KRAS, MAP2K2, MAPK3, non‐V600‐BRAF, RAF1 and a BICD2‐BRAF fusion. A repeated‐measure generalized estimating equation demonstrated that targeted treatment was statistically significantly (1) more likely to result in a complete response (CR), partial response (PR) or stable disease (SD) (odds ratio [OR]: 17.34, 95% CI: 2.19–137.00, p = 0.007), and (2) less likely to result in progression (OR: 0.08, 95% CI: 0.03–0.23, p < 0.0001). Histiocytic neoplasms represent an entity with underappreciated clinical and molecular diversity, poor responsiveness to conventional therapy and exquisite sensitivity to targeted therapy.
An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study
Dunn, Winston , Li, Yanming , Singal, Ashwani K. , Díaz, Luis Antonio , Idalsoaga, Francisco , Ayares, Gustavo , Arnold, Jorge , Ayala-Valverde, María , Pérez, Diego , Gomez, Jaime, Escarate, Rodrigo , Ramírez, Carolina , Morales‐Arráez, Dalia , Qian, Steve , Ahn, Joseph , Buryska, Seth , Mehta, Heer , Dunn, Nicholas , Bumbu, Andreea , Horhat, Adelina , Attar, Bashar, Agrawal, Rohit , Echavaría, Victor , Cuyàs, Berta , Poca, María , Maiwall, Rakhi , Rao, Padaki Nagaraja , Guerra-Salazar, Patricia, Kubánek, Natália , Prado, Verónica , Clemente, Ana , Haider, Tehseen, Chacko, Kristina R. , Romero, Gustavo , Pollarsky, Florencia , Toro, Luis, Yaquich, Pamela, Garrido, María Laura , Dirchwolf, Melisa , Vargas, Vı́ctor , Jiménez, César , García–Tsao, Guadalupe , Ortiz, Guillermo, Kamath, Patrick S. , Shah, Vijay H. , Díaz, Luis A , Idalsoaga, Francisco , Ayares, Gustavo , Arnold, Jorge , Ayala-Valverde, María , Perez, Diego , Ramirez-Cadiz, Carolina , Mehta, Heer , Dunn, Nicholas , Horhat, Adelina , Agrawal, Rohit , Poca, Maria , Soriano, German , Jalal, Prasun K , Kulkarni, Anand V , Skladaný, Lubomir , Pollarsky, Florencia D , Restrepo, Juan C , Mendizabal, Manuel , Marciano, Sebastián , Dirchwolf, Melisa , Vargas, Victor , Jiménez, César , Arrese, Marco , Bataller, Ramon A , Ahn, Joseph C , Singal, Ashwani K , Cuyas, Berta , Dunn, Winston , Simonetto, Douglas A. , Fuentes–López, Eduardo , Zhang, Wei , Waleed, Muhammad Hasnain , Ştefănescu, Horia , Cabezas, Joaquín , Sarin, Shiv Kumar , Jalal, Prasun K. , Tijera, Fatima Higuera‐de la , Kulkarni, Anand V. , Rincón, Diego , Hudson, David, Ortiz, Guillermo, Abraldeṣ, Juan G. , Arrese, Marco , Arab, Juan Pablo

Mayo Clinic

Hepatology | April 12, 2024 | Volume: 80 | Issue: 5 | Pages: 1196-1211

10.1097/hep.0000000000000883 | PMID 38607809 Get It

Background and Aims: Alcohol-associated hepatitis (AH) poses significant short-term mortality. Existing prognostic models lack precision for 90-day mortality. Utilizing artificial intelligence in a global cohort, we sought to derive and validate an enhanced prognostic model. Approach and Results: The Global AlcHep initiative, a retrospective study across 23 centers in 12 countries, enrolled patients with AH per National Institute for Alcohol Abuse and Alcoholism criteria. Centers were partitioned into derivation (11 centers, 860 patients) and validation cohorts (12 centers, 859 patients). Focusing on 30 and 90-day postadmission mortality, 3 artificial intelligence algorithms (Random Forest, Gradient Boosting Machines, and eXtreme Gradient Boosting) informed an ensemble model, subsequently refined through Bayesian updating, integrating the derivation cohort’s average 90-day mortality with each center’s approximate mortality rate to produce posttest probabilities. The ALCoholic Hepatitis Artificial INtelligence Ensemble score integrated age, gender, cirrhosis, and 9 laboratory values, with center-specific mortality rates. Mortality was 18.7% (30 d) and 27.9% (90 d) in the derivation cohort versus 21.7% and 32.5% in the validation cohort. Validation cohort 30 and 90-day AUCs were 0.811 (0.779–0.844) and 0.799 (0.769–0.830), significantly surpassing legacy models like Maddrey’s Discriminant Function, Model for End-Stage Liver Disease variations, age-serum bilirubin-international normalized ratio-serum Creatinine score, Glasgow, and modified Glasgow Scores (p < 0.001). ALCoholic Hepatitis Artificial INtelligence Ensemble score also showcased superior calibration against MELD and its variants. Steroid use improved 30-day survival for those with an ALCoholic Hepatitis Artificial INtelligence Ensemble score > 0.20 in both derivation and validation cohorts. Conclusions: Harnessing artificial intelligence within a global consortium, we pioneered a scoring system excelling over traditional models for 30 and 90-day AH mortality predictions. Beneficial for clinical trials, steroid therapy, and transplant indications, it’s accessible at: https://aihepatology.shinyapps.io/ALCHAIN/.
Transcatheter Pulmonary Valve Replacement With the Harmony Valve in Patients Who Do Not Meet Recommended Oversizing Criteria on the Screening Perimeter Plot
McElhinney, Doff B. , Gillespie, Matthew J. , Cabalka, Allison K. , Morray, Brian H. , Balzer, David T. , Qureshi, Athar M. , Hoskoppal, Arvind , Cabalka, Allison , Morray, Brian H , Qureshi, Athar M , Hoskoppal, Arvind K , Goldstein, Bryan H , McElhinney, Doff B , Aboulhosn, Jamil , Goldstein, Bryan H.

Mayo Clinic

Circulation: Cardiovascular Interventions | April 12, 2024 | Volume: 17 | Issue: 5 | Pages: No page available

10.1161/circinterventions.123.013889 | PMID 38606564 Get It

BACKGROUND: Anatomic selection for Harmony valve implant is determined with the aid of a screening report and perimeter plot (PP) that depicts the perimeter-derived radius along the right ventricular outflow tract (RVOT) and projects device oversizing. The PP provides an estimation of suitability for implant, but its sensitivity as a screening method is unknown. This study was performed to describe anatomic features and outcomes in patients who underwent Harmony TPV25 implant despite a PP that predicted inadequate oversizing. METHODS: We reviewed RVOT anatomic features and measurements in patients who underwent transcatheter pulmonary valve replacement with the Harmony TPV25 device despite a PP that predicted inadequate oversizing. RESULTS: This study included 22 patients. There were no unsuccessful implants or adverse valve-related events. Anatomic features varied, but all patients fit into 1 of 3 anatomic types characterized by differences in RVOT dimensions. Type 1 patients (n=9) had a long RVOT with a choke point and a wide main pulmonary artery. Type 2 patients (n=6) had a short RVOT that was pyramidal in shape, with no choke point, and extensive main pulmonary artery lengthening/expansion during systole. Type 3 patients (n=7) had a short, bulbous main pulmonary artery with a choke point and an open pulmonary artery bifurcation. CONCLUSIONS: Transcatheter pulmonary valve replacement with the Harmony valve is feasible in some patients whose PP fit analysis predicts inadequate oversizing. All cases in this series fit into 1 of 3 anatomic patterns, which are not identified in the screening report. Implanters must review cases individually to assess the feasibility of the implant.
Clinical Decision Making in Inflammatory Bowel Disease Mimics: Practice Management from Inflammatory Bowel Disease LIVE
Fiske, Hannah W. , Shah, Samir A. , Al-Bawardy, Badr , Binion, David G. , Bohm, Matthew , Brand, Myron, Cohen, Benjamin L, Dueker, Jeffrey, Engels, Michael , Fine, Sean , Förster, E , Gaidos, Jill , Ginsburg, Philip, Goyal, Alka , Hanson, John S. , Herfath, Hans, Hull, Tracy L. , Kelly, Colleen , Lazarev, Mark , Levy, L. Campbell, Melia, Joanna , Philpott, Jessica, Qazi, Taha , Watson, Andrew , Wexner, Steven D. , Williams, Emmanuelle, Al‐Bawardy, Badr , Al-Bawardy, Badr , Bohm, Matthew , Fine, Sean , Forster, Erin , Gaidos, Jill K J , Hull, Tracy , Melia, Joanna , Qazi, Taha , Regueiro, Miguel , Wexner, Steven D , Ward, Chris , Holubar, Stefan D. , Barnes, Edward L. , Clarke, Kofi , Cohen, Benjamin L, Cross, Raymond K. , Farraye, Francis A. , Hanson, John, Philpott, Jessica R., Siegel, Corey A , Regueiro, Miguel

Mayo Clinic

Crohn's & Colitis 360 | April 10, 2024 | Volume: 6 | Issue: 2 | Pages: No page available

10.1093/crocol/otae022 | PMID 38720935 Get It

Abstract Background Since 2009, inflammatory bowel disease (IBD) specialists have utilized “IBD LIVE,” a weekly live video conference with a global audience, to discuss the multidisciplinary management of their most challenging cases. While most cases presented were confirmed IBD, a substantial number were diseases that mimic IBD. We have categorized all IBD LIVE cases and identified “IBD-mimics” with consequent clinical management implications. Methods Cases have been recorded/archived since May 2018; we reviewed all 371 cases from May 2018–February 2023. IBD-mimics were analyzed/categorized according to their diagnostic and therapeutic workup. Results Confirmed IBD cases made up 82.5% (306/371; 193 Crohn’s disease, 107 ulcerative colitis, and 6 IBD-unclassified). Sixty-five (17.5%) cases were found to be mimics, most commonly medication-induced (n = 8) or vasculitis (n = 7). The evaluations that ultimately resulted in correct diagnosis included additional endoscopic biopsies (n = 13, 21%), surgical exploration/pathology (n = 10, 16.5%), biopsies from outside the GI tract (n = 10, 16.5%), genetic/laboratory testing (n = 8, 13%), extensive review of patient history (n = 8, 13%), imaging (n = 5, 8%), balloon enteroscopy (n = 5, 8%), and capsule endoscopy (n = 2, 3%). Twenty-five patients (25/65, 38%) were treated with biologics for presumed IBD, 5 of whom subsequently experienced adverse events requiring discontinuation of the biologic. Many patients were prescribed steroids, azathioprine, mercaptopurine, or methotrexate, and 3 were trialed on tofacitinib. Conclusions The diverse presentation of IBD and IBD-mimics necessitates periodic consideration of the differential diagnosis, and reassessment of treatment in presumed IBD patients without appropriate clinical response. The substantial differences and often conflicting treatment approaches to IBD versus IBD-mimics directly impact the quality and cost of patient care.
Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study
Crane, Genevieve M. , Geyer, Julia T. , Wang, Sa A. , Li, Ke David, Davis, Adam R. , Bosler, David , Bueso‐Ramos, Carlos E. , Bagg, Adam , Hasserjian, Robert P. , Hsi, Eric D , Thakral, Beenu , Wool, Geoffrey D. , Boiocchi, Leonardo , Arber, Daniel A. , George, Tracy I. , Orazi, Attilio , Hsi, Eric D. , Rogers, Heesun J.

Mayo Clinic

American Journal of Clinical Pathology | April 10, 2024 | Volume: 162 | Issue: 3 | Pages: 233-242

10.1093/ajcp/aqae033 | PMID 38597584 Get It

Abstract Objectives Myeloproliferative neoplasm, unclassifiable (MPN-U, revised to MPN, not otherwise specified in the fifth edition of the World Health Organization classification) is a heterogeneous category of primary marrow disorders with clinical, morphologic, and/or molecular features that preclude classification as a more specific MPN subtype due to stage at diagnosis, overlapping features between MPN subtypes, or the presence of coexisting disorders. Compared with other MPN subtypes, the contribution of the mutational landscape in MPN-U in conjunction with other clinical and morphologic biomarkers to prognosis has been less well investigated. Methods We performed a multicenter, retrospective study of MPN-U (94 cases) to better define the clinicopathologic features, genetic landscape, and clinical outcomes, including subgroups of early-stage, advanced-stage, and coexisting disorders. The Dynamic International Prognostic Scoring System (DIPSS) plus scoring system was applied to assess its relevance to MPN-U prognosis. Results Multivariate analysis demonstrated bone marrow blast count and DIPSS plus score as statistically significant in predicting overall survival. Univariate analysis identified additional potential poor prognostic markers, including abnormal karyotype and absence of JAK2 mutation. Secondary mutations were frequent in the subset analyzed by next-generation sequencing (26/37 cases, 70.3%) with a borderline association between high molecular risk mutations and overall survival. Conclusions This study, as one of the largest of MPN-U studies incorporating both clinicopathologic and molecular data, moves toward identification of biomarkers that better predict prognosis in this heterogeneous category.
Conjugal Synucleinopathies: A Clinicopathologic Study
Adler, Charles H. , Halverson, Matthew , Shill, Holly A. , Driver‐Dunckley, Erika, Mehta, Shyamal H. , Caviness, John N., Belden, Christine M. , Long, Kathy E., Beach, Thomas G. , Driver-Dunckley, Erika, Beach, Thomas G , Adler, C H , Zhang, Nan , Driver‐Dunckley, Erika , Atri, Alireza , Serrano, Geidy E. , Shprecher, David , Sabbagh, Marwan Noel

Mayo Clinic

Movement Disorders | April 10, 2024 | Volume: 39 | Issue: 7 | Pages: 1212-1217

10.1002/mds.29783 | PMID 38597193 Get It

AbstractBackgroundWhile preclinical studies have shown that alpha‐synuclein can spread through cell‐to‐cell transmission whether it can be transmitted between humans is unknown.ObjectivesThe aim was to assess the presence of a synucleinopathy in autopsied conjugal couples.MethodsNeuropathological findings in conjugal couples were categorized as Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease with Lewy bodies (ADLB), incidental Lewy body disease (ILBD), or no Lewy bodies.ResultsNinety conjugal couples were included; the mean age of death was 88.3 years; 32 couples had no Lewy bodies; 42 couples had 1 spouse with a synucleinopathy: 10 PD, 3 DLB, 13 ADLB, and 16 ILBD; 16 couples had both spouses with a synucleinopathy: in 4 couples both spouses had PD, 1 couple had PD and DLB, 4 couples had PD and ADLB, 2 couples had PD and ILBD, 1 couple had DLB and ADLB, in 3 couples both had ADLB, and 1 couple had ADLB and ILBD. No couples had both spouses with ILBD.ConclusionsThis large series of 90 autopsied conjugal couples found 16 conjugal couples with synucleinopathies, suggesting transmission of synucleinopathy between spouses is unlikely. © 2024 International Parkinson and Movement Disorder Society.
Frameless, Virtual Cone Linac-based Stereotactic Radiosurgery for Essential & Parkinsonian Tremor: A Phase I/II Prospective Clinical Trial (S35.001)
Thomas, Evan , Walker, Harrison C. , Middlebrooks, Erik H. , McCullough, Benjamin, Stover, Natividad , Guthrie, Barton L. , Popple, Richard A. , Fiveash, John B. , Bredel, Markus , Middlebrooks, Erik H , Sung, Victor , Standaert, David G. , Bentley, J. Nicole , Holland, Marshall T.

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000208138 Get It